HYPMED researchers developing new hybrid PET/MRI system for improved breast cancer diagnosis

Huge Two-Day Clean Sweep Auction July 24-25th. Click Here to Bid!

advertisement
Current Location:
>
> This Story

Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

More HCB News

Misdiagnosis behind a third of malpractice cases Researchers from Johns Hopkins look at 55,000 malpractice claims

With stock value up 51 percent, is Mindray too pricey? Valuation has recently soared to $29 billion

Study advises personalized breast cancer screenings for cancer survivors May benefit from MR alone, rather than MR and mammography

Optimizing the EHR user experience Examining how we got here, and the best path to move ahead

FDA gives RaySearch green light for RayStation 8B platform First treatment planning system to offer machine learning applications

Rising workloads and technology are main causes of clinician burnout Called a 'public health crisis' by 92 percent of survey respondents

The road ahead for breast density awareness It's been a good year for advocacy, here's what happens next

Some medical devices exempted from China tariffs Among the recently announced 110 exemptions

Providers in need of more specialists, fewer primary care physicians, says report Facing projected shortage in a number of specialties

The feds want to give consumers more control over their data — are healthcare organizations prepared?

HYPMED researchers developing new hybrid PET/MRI system for improved breast cancer diagnosis

Press releases may be edited for formatting or style
Vienna, 2016-01-27 - HYPMED -- Breast cancer is the most common type of female cancer and continues to be one of the main causes of cancer death in women. Despite the advances made in modern medicine and contemporary targeted therapies, the stage of breast cancer at the time of diagnosis is still the most important driver of patient survival. This means that there is an obvious and persisting need for an improved early diagnosis of this disease.

The project Digital Hybrid Breast PET/MRI for Enhanced Diagnosis of Breast Cancer, HYPMED for short, will develop a hybrid system of two medical imaging modalities (MRI and PET) for improved diagnosis of breast cancer and personalised therapy control. A European consortium made up of nine partners from leading universities, research organisations and industry has recently started their ambitious research initiative. “The HYPMED project combines visionary clinical expertise with excellence in physical and engineering sciences and the developed technology will greatly help us to choose an appropriate treatment that is exactly right for a given cancer in a given woman”, states, Prof. Christiane Kuhl from University Hospital Aachen and Scientific Coordinator of the project.

Story Continues Below Advertisement

New & Refurbished C-Arm Systems. Call 702.384.0085 Today!

KenQuest provides all major brands of surgical c-arms (new and refurbished) and carries a large inventory for purchase or rent. With over 20 years in the medical equipment business we can help you fulfill your equipment needs



The project`s ambition is to develop a radiofrequency coil that can be connected to any regular clinical MR scanner and transform the device into a high-resolution PET/MRI hybrid system, which can be used to identify even the smallest breast cancer foci and better characterize the cancer as well as its response to therapy. Patients will also benefit as the radiation dose of the new technology will, in contrast to other PET-MRI examinations, be comparable to a regular digital mammogram.

The HYPMED approach is also likely to be transferrable to other clinical applications, such as prostate cancer detection and hybrid cardiac imaging. “We believe that this will introduce a paradigm shift in the field of PET/MR hybrid imaging with many new applications in other diseases. With the success of the HYPMED project, we will open up a whole new chapter of medical hybrid imaging,” says Prof. Schulz, head of the Department the Physics of Molecular Imaging Systems at Aachen.

The innovative concept also convinced the reviewers of the EU Horizon 2020 research program, who awarded the HYPMED project proposal the highest evaluation score possible.

Background
The HYPMED project started on January 1st, 2016 and involves, over a 4-year period, recognized organisations and industry partners from all over Europe: European Institute for Biomedical Imaging Research, AT (Project Coordinator); University Hospital Aachen, DE (Scientific Coordinator), Forschungszentrum Jülich, DE; Medical University of Vienna, AT; Technical University Delft, NL; University Hospital Münster, DE; NORAS MRI Products GmbH, DE; Futura Composites, NL; INTRASENSE, FR;
Philips Electronics, NL.

The HYPMED project receives funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 667211

Press contact
Pamela Zolda
pzolda@eibir.org mailto:pzolda@eibir.org
+43 533 40 64 538

www.eibir.org http://www.eibir.org

Related:


You Must Be Logged In To Post A Comment